The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 21, 2020
Filed:
Aug. 29, 2018
Applicant:
Acorda Therapeutics, Inc., Ardsley, NY (US);
Inventor:
Mark Marchionni, Arlington, MA (US);
Assignee:
Acorda Therapeutics, Inc., Ardsley, NY (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 49/00 (2006.01); A61K 38/18 (2006.01); C07K 14/475 (2006.01); C07K 14/48 (2006.01); C07K 14/00 (2006.01); A61K 35/34 (2015.01); A61K 38/16 (2006.01); A61K 45/00 (2006.01); A61K 38/17 (2006.01); A61K 47/42 (2017.01); C07K 14/485 (2006.01); A61P 9/06 (2006.01); A61P 9/00 (2006.01); A61P 9/04 (2006.01); C07K 14/47 (2006.01); C07K 14/71 (2006.01); A61P 9/10 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/4756 (2013.01); A01K 2217/05 (2013.01); A61K 35/34 (2013.01); A61K 38/00 (2013.01); A61K 38/16 (2013.01); A61K 38/17 (2013.01); A61K 38/1709 (2013.01); A61K 38/18 (2013.01); A61K 38/1883 (2013.01); A61K 45/00 (2013.01); A61K 47/42 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/6031 (2013.01); A61K 2300/00 (2013.01); A61P 9/00 (2018.01); A61P 9/04 (2018.01); A61P 9/06 (2018.01); A61P 9/10 (2018.01); C07K 14/00 (2013.01); C07K 14/47 (2013.01); C07K 14/475 (2013.01); C07K 14/485 (2013.01); C07K 14/71 (2013.01); C07K 2319/00 (2013.01); C12N 2830/85 (2013.01); G01N 33/5061 (2013.01); G01N 33/68 (2013.01); G01N 2333/4756 (2013.01); G01N 2333/485 (2013.01); G01N 2333/71 (2013.01); G01N 2500/10 (2013.01); G01N 2800/32 (2013.01); G01N 2800/325 (2013.01); G01N 2800/52 (2013.01);
Abstract
The invention features methods of treatment and diagnosis using NRG-2 polypeptides, nucleic acid molecules, and antibodies. The invention also provides novel NRG-2 polypeptides and nucleic acid molecules.